Incyte Biosciences International Sàrl clinical trials
Acquired by Incyte Corporation, Jun 1, 2016 · source ↗
The registry lists 10 studies whose lead sponsor is Incyte Biosciences International Sàrl. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Before and after it joined Incyte Corporation
- First submitted before Incyte Biosciences International Sàrl became part of Incyte Corporation
- 1
- First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- 9
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Incyte Biosciences International Sàrl10 studies
Something wrong with this grouping? Tell us on the Incyte Corporation page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Incyte Corporation studies →
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05287113Phase 2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT02923349Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnNCT05359692Phase 2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03241173Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedNCT03277352Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid TumorsCompletedNCT02697591Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted before Incyte Biosciences International Sàrl became part of Incyte Corporation
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"WithdrawnNCT03515785
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation